榴莲视频成版APP下载,榴莲视频网站入口,榴莲视频官网成人,榴莲视频APP下载黄色

Biological Activity:

4SC-202 is a potent, selective and orally bioavailable HDAC/LSD1 dual Inhibitor. It inhibits class I HDAC with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). 4SC-202 has very high selectivity over ClassIIa/IIb/III HDACs. In HeLa cells, it induces hyperacetylation of histone H3 with EC50 of 1.1 μM. It induces a G2/M cell cycle arrest by interfering with the normal development of the mitotic spindle and causing collapsed spindle apparatus and multiple nucleation centres. In addition, 4SC-202 shows a broad anti-proliferative activity towards human cancer cell lines with a mean IC50 of 0.7 μM. In vivo it shows pronounced and robust anti-tumor activity in both A549 NSCLC xenograft and RKO27 colon carcinoma model. Currently it is in phase I trials for patients with advanced haematological tumours.

How to Use:

In vitro: 4SC-202 was used at 10 µM final concentration in various in vitro assays.
In vivo: 4SC-202 was dosed to A549 NSCLC xenograft model and RKO27 colon carcinoma xenografts model orally at 120 mg/Kg once per day.

Reference:

• 1. S.W.Henning, et al. Preclinical characterization of 4SC-202, a noval isotype specific HDAC inhibitor.
• 2. http://www.4sc.de/product-pipeline/clinical/4SC-202